BioWorld 11th June 2019, page-2

Thank you for sharing!
Interesting quote from page 9 "we estimate that the animal cancer marketin itself is worth about AU$500 million to AU$600 million, andthere is a lot of room for a drug that doesn’t have toxicity"
and page 10 from Roger Aston "If you look at the company’s share price, we’re a microcap,and yet here we are going into a major phase II trial. This is verytypical of the Aussie market; they want to see you reach yourgoal before we get funding."
Looks Like they are very aware of just how undervalued Pharmaust is at this point in the trials. Certainly echoes posts here discussing how undervalued biotechs listed in Australia are as opposed to in the US. It's quite encouraging to hear management acknowledging this imo.